Sun Pharma board to meet on 12 Oct 2026 to approve NCD issuance up to ₹15,000 Cr
Sun Pharma.Inds. · Pharmaceuticals & Biotechnology
What the filing says
- Board meeting scheduled for Monday, 12 October 2026
- To consider approval of listed, rated, unsecured, redeemable non-convertible debentures (NCDs)
- Issuance via private placement, aggregate amount not exceeding ₹15,000 Crore
Why it's rated notable: not yet binding (letter of intent, proposal or subject to approvals)
Original filing
Board Meeting Intimation for Consideration And Approval Of The Issuance Of Listed, Rated, Unsecured, Redeemable, Non-Convertible Debentures
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Sun Pharma.Inds.
- Fundraise / allotmentNotableSun Pharma board approves NCDs up to ₹10,000 crore; independent director Doshi resigns
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentRane Holdings LtdRane Holdings approves ₹80.85 crore investment in ZF Lifetec Rane JV rights issue
- Fundraise / allotmentCapital Infra TrustCapital Infra Trust submits post-Institutional Placement unit holding pattern
- Fundraise / allotmentCapital Infra TrustCapital Infra Trust raises ₹1,115 crore via QIP for acquiring six HAM road assets
- Fundraise / allotmentPaisalo Digital LtdPaisalo Digital Limited approves Q2 and H1 FY2026-27 unaudited financial results
- Fundraise / allotmentBluestone JewelBlueStone Jewellery to raise up to ₹300 crore via non-convertible debentures
- Fundraise / allotmentAvalon Technologies LtdAvalon Technologies Limited announces Board meeting on Oct 27, 2026 for fund raising
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.